Summary
Gilead Sciences, Inc. reported robust growth in its 2011 fiscal year, with total revenues reaching $8.39 billion, a 5% increase year-over-year, primarily driven by a 10% rise in product sales to $8.10 billion. The company's antiviral franchise, particularly sales of Atripla and Truvada, was the main growth engine. Gilead also made significant strategic moves, highlighted by the pending $11.1 billion acquisition of Pharmasset, Inc., aimed at strengthening its position in the hepatitis C market with the acquisition of the promising drug candidate GS-7977. The company is actively managing its pipeline, with advancements in HIV treatments including the submission of a new drug application for the 'Quad' single-tablet regimen and the launch of Complera/Eviplera. While facing increasing competition and ongoing pricing pressures, especially in Europe, Gilead demonstrated strong financial management, with a significant increase in cash reserves and continued stock repurchase programs. Investors should note the ongoing legal challenges related to patent defenses for key products and the potential impact of U.S. healthcare reform on future revenue and profitability.
Financial Highlights
54 data points| Revenue | $8.39B |
| Cost of Revenue | $2.12B |
| Gross Profit | $6.26B |
| R&D Expenses | $1.23B |
| SG&A Expenses | $1.24B |
| Operating Expenses | $4.60B |
| Operating Income | $3.79B |
| Interest Expense | $205.42M |
| Net Income | $2.80B |
| EPS (Basic) | $1.81 |
| EPS (Diluted) | $1.77 |
| Shares Outstanding (Basic) | 1.55B |
| Shares Outstanding (Diluted) | 1.58B |
Key Highlights
- 1Total revenues grew 5% to $8.39 billion in 2011, with product sales increasing 10% to $8.10 billion, primarily driven by the antiviral franchise.
- 2Gilead announced a $11.1 billion acquisition of Pharmasset, Inc., to bolster its Hepatitis C (HCV) pipeline with the addition of GS-7977, a highly potent nucleotide analog.
- 3The HIV franchise continues to be a strong performer, with significant sales growth from Atripla and Truvada, and the launch of Complera/Eviplera, with the 'Quad' single-tablet regimen awaiting FDA approval.
- 4Research and Development (R&D) expenses increased by 15% to $1.23 billion in 2011, reflecting investments in clinical studies and strategic acquisitions.
- 5The company's cash, cash equivalents, and marketable securities significantly increased to $9.96 billion by the end of 2011, partly due to debt financing for the Pharmasset acquisition.
- 6Gilead is actively engaged in patent litigation to defend its key products against generic manufacturers, which could impact future revenues if unsuccessful.
- 7The company highlighted its commitment to global access through various programs, including providing HIV and other medicines at reduced prices in developing countries.